Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025

Stock Information for CytoSorbents Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CytoSorbents Corporation

CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer
CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen
CytoSorbents Provides DrugSorb-ATR Regulatory Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.